What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock Drop
Specializing in organ preservation technology, this medical device innovator reported a notable insider sale amid ongoing sector challenges.
What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock Drop
Overview
Thomas J. Gunderson, a director at TransMedics Group (NASDAQ:TMDX), reported the direct sale of 9,624 shares of Common Stock in an options-related transaction valued at approximately $722,000, as disclosed in a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($75.06); post-transaction value based on June 15, 2026 market close, as reflected in the Form 4 ($75.06).
Details
* 1-year price change calculated as of June 15, 2026.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
